Sébastien Faure

Introduction Uterine cancer is the most common gynecologic malignancy in the United States with an estimated 66,000 new cases and over 13,000 deaths in 2023 [[1], [2], [3]]. Prevalence has continued to increase, attributed in part to the ongoing obesity epidemic [4]. Most cases of uterine cancer are diagnosed at an early-stage and are treated primarily with surgery. Adjuvant therapy with radiation or chemotherapy may be indicated depending on stage and/or tumor characteristics [5,6].

Abstract : Simple Summary Health agencies in several countries have different recommendations regarding the consumption of soy isoflavones (phytoestrogens) in breast cancer (BC) survivors. This review is an analysis of prospective cohort studies published between 2009 and 2020 to determine whether there is a rationale for advising avoidance of soy in dietary supplements and/or foods in women with a history of BC.